REPORT TO THE LEGISLATURE
Pursuant to P.A. 121 of 2024
Section 607
FY 2025 Quarter 2
Michigan Department of Corrections

Sec. 607. (2) The department must submit quarterly reports on the status of establishment and operation of medication-assisted treatment clinics. A report under this subsection must include but not be limited to all of the following:
(a) Clinic site locations
(b) Staffing levels.
(c) Expenditures on staffing and supplies, including oral and injectable medications.
(d) Number of prisoners treated.
(e) Number of prisoners requiring treatment but not yet receiving treatment.

Michigan Department of Corrections has 26 correctional facilities prescribing naltrexone and 17 of those correctional facilities are currently prescribing buprenorphine products for Medications for Assisted Treatment (MAT) for those diagnosed with an Opioid Use Disorder. In the second quarter of FY25 the department has successfully increased the number of correctional facilities offering both naltrexone and buprenorphine from 15 facilities from quarter one to 17 facilities while continuing to maintain the previously implemented facilities.

The clinic site locations are Bellamy Creek Correctional Facility – Ionia, Carson City Correctional Facility– Carson City, Central Michigan Correctional Facility– St. Louis, Charles E. Egeler Reception and Guidance Center – Jackson, G. Robert Cotton Correctional Facility – Jackson, Gus Harrison Correctional Facility – Adrian, Ionia Correctional Facility – Ionia, Macomb Correctional Facility – New Haven, Marquette Branch Prison – Marquette, Muskegon Correctional Facility – Muskegon, Oaks Correctional Facility – Manistee, Parnall Correctional Facility – Jackson, Richard A. Handlon Correctional Facility – Ionia, St. Louis Correctional Facility – St. Louis, Thumb Correctional Facility – Lapeer, Women's Huron Valley Correctional Complex – Ypsilanti, and Woodland Correctional Facility – Whitmore Lake.

The information below is for the second quarter for FY25 and will be updated on the third quarter report as we have not received all the expenses for March due to pending invoices.

Site locations selected	Buprenorphine Sites	17
	Naltrexone Sites	26
	New MAT sites established	0
Staffing levels	Filled MAT Positions	58.25
	Vacant MAT Positions	9.15
Expenditures on staffing	**TOTAL COST:**	**$1,586,577.79**

Expenditures on supplies, including oral and injectable medications	*Sublocade:	$383,517.72
	Suboxone:	$63,490.13
	Naltrexone:	$21,764.80
	TOTAL COST:	**$468,772.65**
	($1 million dollars were used from the Opioid Settlement Fund to pay for Sublocade in Q2)*	
Number of prisoners treated	Number of inmates that received at least 1 dose of MAT medication	
	TOTAL:	**1,807**
Number of prisoners requiring treatment but not yet receiving treatment	**TOTAL:**	**2,910**

Below are the updated expenses, staffing levels, and information from quarter one as we received all invoices after the quarter one report was submitted.

Site locations selected	Buprenorphine Sites	15
	Naltrexone Sites	26
	New MAT sites established	2
Staffing levels	Filled MAT Positions	33.5
	Vacant MAT Positions	33.9
Expenditures on staffing	**TOTAL COST:**	**$976,406.56**
Expenditures on supplies, including oral and injectable medications	*Sublocade:	$519,414.84
	Suboxone:	$78,311.97
	Naltrexone:	$43,187.09
	TOTAL COST:	**$640,913.90**
	($1 million dollars were used from the Opioid Settlement Fund to pay for Sublocade in Q1)*	
Number of prisoners treated	Number of inmates that received at least 1 dose of MAT medication	
	TOTAL:	**1,863**
Number of prisoners requiring treatment but not yet receiving treatment	**TOTAL:**	**2,959**